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Primary glomerulonephritis may recur in kidney allo-Kidney transplantation in patients with IgA mesangial glomer-
grafts and can affect graft survival particularly in the long-ulonephritis.
Background. Strategies for treating IgA glomerulonephritis term [1, 2]. IgA mesangial glomerulonephritis (IgAGN)
(IgAGN) are controversial, particularly with regards to the long- is the most frequent type of glomerulonephritis and can
term results of kidney transplantation, including the risk of recur- be progressive in one third to one fourth of the cases.rence of IgAGN post-transplant and the impact of this recur-
As for most other renal diseases, also for IgAGN, renalrence on graft survival.
Methods. The outcomes of 106 adults transplanted because transplantation is considered to be the treatment of choice,
of a biopsy-proven IgAGN and of 212 patients without IgAGN although the possibility of recurrence on the kidney allo-
transplanted during the same period were analyzed. To evalu- graft is well established [3]. However, there are different
ate the risk of recurrence, patients with hematuria, proteinuria,
views about the long-term results of renal transplanta-or an increase in plasma creatinine were submitted to allograft
tion in IgAGN, the actual risk of recurrence, and thebiopsy. Factors influencing recurrence and the impact of recur-
rence on graft survival were analyzed. impact of recurrence on allograft function and survival.
Results. The ten-year patient (0.93 vs. 0.92) and graft survival This study retrospectively analyzed our own experi-
(0.75 vs. 0.82) probabilities were not significantly different be- ence with 106 renal transplant patients who had biopsy-tween IgAGN patients and controls. Only plasma creatinine
proven IgAGN as a cause of end-stage renal failure inand proteinuria at six months were associated with an increased
relative risk (RR) of graft failure (RR 2.79 and 5.94, respec- order to evaluate the following: (1) ten-year patient and
tively). Histological recurrence of IgA glomerulonephritis was graft survival probability compared with 212 controls ob-
diagnosed in 37 patients. Younger age (RR 2.63), increased served over the same period; (2) relative impact of the
plasma creatinine (RR 2.39), and proteinuria (RR 6.02) at six
donor source on graft survival; (3) probability and time ofmonths were associated with the risk of recurrence. If protein-
biopsy-proven recurrence; (4) factors correlated with re-uria and plasma creatinine at six months were considered in
the Cox model, IgA recurrence per se was not associated with currence; and (5) impact of recurrence on graft survival.
an increased risk of graft failure (P  0.181). The main causes
of graft failure were glomerulonephritis in patients with recur-
rence of IgAGN and chronic rejection in patients without re- METHODS
currence.
PatientsConclusions. The ten-year graft survival rate was similar in
patients with IgAGN or other renal diseases. At least 35% All adult (18 years) patients who received a first kid-
IgAGN patients had biopsy-proven recurrence, and younger ney transplantation at Ospedale Maggiore of Milan be-
patients were more prone to the risk of recurrence. Recurrence
tween July 1973 and September 1999 because of a biopsy-did not affect the ten-year graft survival.
proven IgAGN were selected for this study. To assess the
impact of recurrent IgAGN on the long-term outcome
better, four IgAGN patients and 27 potential controls
whose allograft failed within the sixth post-transplant
1 See Editorial by Hogg, p. 2033. month and seven IgAGN patients whose follow-up was
shorter than one year were excluded. A control group,Key words: graft survival, renal transplantation, end-stage renal failure,
primary glomerulonephritis. comprised of renal allograft recipients who were trans-
planted immediately before and after the patients with
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among the control patients had a suspicion of IgAGN Statistical methods
as their original renal disease; 30 patients were diagnosed Cumulative probability of graft survival and of recur-
as having polycystic renal disease, 40 had a urological rence was estimated according to Kaplan and Meier [6].
disease, 72 had a biopsy-proven glomerular or interstitial The prognostic relevance of baseline covariates for uni-
disease, 10 had diabetic nephropathy, 20 had hyperten- variate and multivariate analyses was assessed by means
sive nephrosclerosis, and 40 had a miscellaneous well- of stratified Cox’s models, the two strata being control
defined disease (hemolytic uremic syndrome, cortical ne- and IgA nephritis patients.
phrosis, analgesic nephropathy, etc.). For these analyses, the continuous variables were cate-
gorized as follows: age 30 or 30 years; time between
Immunosuppression
the diagnosis of IgAGN on native kidneys and the start
Most patients with IgAGN and their controls were of dialysis 72 or 72 months; length of dialysis 26 or
treated from the begining with cyclosporine. Fifty-six of 26 months; proteinuria 1.0 or 1.0 g/day. For plasma
106 (52.8%) patients in the IgAGN group and 110 of creatinine, the natural logarithm transformed values
212 (51.9%) patients in the control group were initially were used in the Cox model and dichotomized according
treated with a triple therapy (cyclosporine plus azathio- to the median ( or1.5 dL) for Kaplan-Meier survival
prine or mycophenolate mofetil, plus steroids). Twenty- estimates. For non-statistically significant results of a
seven (25.5%) IgAGN patients and 58 (27.3%) controls linear, quadratic and cubic trend of the hazard function
were treated with a double therapy (cyclosporine plus of the graft survival and IgAGN relapse tested by the
steroids). Five (4.7%) IgAGN patients and seven (3.3%) Cox regression models with cubic splines [7], continuous
controls were treated with cyclosporine alone. Eight covariates have been dichotomized according to their
(7.5%) IgAGN patients and 14 (6.6%) controls received median for two reasons: ease of interpretation and to
cyclosporine in combination with rapamycin and ste- not rely on the assumption that the effect of a covariate’s
roids. Six (5.7%) IgAGN patients and 14 (6.1%) controls value on the hazard function is exponential, as required
were treated with tacrolimus and steroids. Finally, four by the proportional hazards model.
IgAGN patients (3.8%) and nine controls (4.2%) were Comparisons between the classes of factors possibly
treated with azathioprine plus steroids. related to recurrence were carried out by means of a Log-
rank test [8]. Time-dependent variables (recurrence of
Diagnosis of recurrence
IgAGN) were considered according to the correspond-
The diagnosis of recurrence of IgAGN was based on ing Cox’s model [9]. In evaluating the mean plasma creat-
a graft biopsy showing mesangial deposits of IgA on im- inine levels, patients who had to return to dialysis were
munofluorescence. In patients with a biopsy-proven di- considered to have a plasma creatinine of 10 mg/dL,
agnosis of IgAGN recurrence, the appearance of micro- while in patients who died, the last value before death
scopic hematuria (more than 1 erythrocyte/high power was taken into account. The slope of the reciprocal of
field at400 after a standardized handling of the urinary the plasma creatinine for each patient was calculated by
samples [4]) or proteinuria more than 0.5 g per day that means of least-squares linear regression.
was not attributable to other causes were considered to
be the first sign of recurrence.
RESULTSGraft loss was attributed to recurrent IgAGN when
renal histology showed diffuse mesangial proliferative Of the 1577 renal transplants performed between July
1973 and September 1999, 106 (6.7%) patients withlesions of the glomeruli accompanied by segmental ne-
crosis of the tuft, extracapillary proliferation, and glo- IgAGN met the criteria for being enrolled in this retro-
spective analysis. The demographic characteristics ofmerulosclerosis. These lesions were usually associated
with severe proteinuria and hematuria. Chronic rejection these patients did not show differences with those of 212
controls (Table 1) with the exception of gender.was diagnosed when the biopsy showed diffuse intersti-
tial fibrosis associated with transplant arteriopathy, de- The ten-year patient survival probability was 0.93 (95%
CI, 0.84 to 1.00) for patients with IgAGN and 0.92 (95%fined by the presence of pronounced intimal prolifera-
tion with invasion of spindle-shaped myocytes associated CI, 0.86 to 0.98) for controls (Fig. 1). Four patients with
IgAGN (3.8%) died. Causes of death were cardiovascu-with a variable infiltrate of mononuclear cells, mostly
located in subendothelial cells [5]. Usually proteinuria lar complications in three patients and cancer in the
fourth patient. In the control group, eight patients (3.8%)was mild or moderate (1 g per day). When the pre-
viously described glomerular and vascular lesions were died, four from infection and four from cardiovascular
complications.coexisting, the graft loss was attributed to a mixture of
IgAGN and chronic rejection. Neither interstitial fibrosis Without considering failures that occurred in the first
six months, the ten-year graft survival rate was 0.75 (95%nor tubular atrophy alone was considered supportive of a
diagnosis for recurrent IgAGN nor for chronic rejection. CI, 0.61 to 0.89) in the IgAGN group, which was not
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Table 1. Demographic characteristics of renal transplant recipients teinuria, in five (13.5%) by an increase in plasma creati-
with IgA glomerulonephritis (IgAGN) and controls
nine, while one patient (2.7%) who received a protocol
IgAGN Controls biopsy did not have any sign of IgAGN at the moment
(N  106) (N  212) P of biopsy. The median time of appearance of clinical
Age years 38.312.0 37.514.5 NS signs of recurrence was 33.5 months (range 2 to 210) and
median, min–max 38.5, 18–60 37, 18–63
the median time for documented histological recurrenceSex male/female 80/26 126/86 0.007
(75.5%/24.5%) (59.4%/40.6%) was 52.0 months; three patients received a diagnosis of
Living/cadaveric donors 21/85 42/170 NS recurrence after more than ten years (Fig. 3). Patients
(19.8%/80.2%) (19.8%/80.2%)
with recurrence were significantly younger than patientsLength of dialysis months 33.932.2 39.740.7 NS
median, min–max 21, 0–135 29, 0–339 without recurrence. The difference in proteinuria at six
Mean follow up months 70.450.5 78.656.5 NS months was also statistically significant but clinically ir-
median, min–max 61, 12–120 68, 12–120
relevant (Table 3).
Using multivariate analysis, log-transformed plasma
creatinine at six months, proteinuria and age at trans-
plantation (P 0.0065) were significantly associated withsignificantly different (P  0.317) from the 0.82 (95%
CI, 0.74 to 0.90) obtained in the control group (Fig. 2). the risk of IgAGN recurrence. Patients with a unit in-
When IgAGN patients and controls were considered crease of the log-transformed plasma creatinine (corre-
together, sex (P  0.729), age (P  0.327), length of sponding to an increase of 2.7 mg/dL) had a RR of 3.6
dialysis (P 0.440), donor source (P 0.514), and acute and patients with proteinuria 1.0 g/day had a RR of
rejection (P  0.287) did not significantly influence the 4.9. Patients younger than 30 years had a RR of 2.6
graft survival. Otherwise, log-transformed plasma creati- (Table 4).
nine at six months and proteinuria at six months (1 or It is difficult to assess the role of mycophenolate mo-
1 g/day) turned out to be the only prognostic factors fetil or rapamycin in renoprotection because of the small
in the multivariate stratified Cox’s model (Table 2). Pa- number of patients. Of the 22 patients given mycopheno-
tients with a unit increase of the log-transformed plasma late mofetil, two had a biopsy-proven recurrence of
creatinine (corresponding to an increase of 2.7 mg/dL IgAGN, and seven of the eight patients given rapamycin
in its original scale) had a relative risk (RR) of 12.9. had a recurrence.
Patients with proteinuria 1.0 g/day had a RR of 4.6. During the ten-year post-transplantation period, five
The five-year survival rate was similar in IgAGN pa- (13.5%) graft failures and one death occurred in the
tients who received a cadaveric kidney (0.93; 95% CI group with IgAGN recurrence versus six (8.7%) graft fail-
0.87 to 0.99) and those transplanted with a living donor ures and one death in those without the recurrence. In
(0.89; 95% CI 0.75 to 1.00). The probability was esti- the group with recurrence, the causes of graft failure
mated from the baseline to five-year values, as thereafter were progressive glomerulonephritis in four patients and
the number of patients at risk in the living donor group chronic rejection in one patient. All six patients in the
was too low for sufficient precision. group without recurrence lost their allograft because of
The cumulative incidence at three months of acute chronic rejection. The median time of failure was 51.5
rejections was 29 out of 106 (27.3%, 95% CI, 19.2 to months (range of 19 to 102) in the group with recurrence
36.9%) in the IgAGN group and 82 out of 212 (38.7%,
versus 42 months (range 10 to 114) in the group without95% CI, 32.1 to 45.6%) in the control group. The mean
recurrence. When considering recurrence alone as aslope of the reciprocal of the plasma creatinine from base-
time-dependent covariate in the Cox model, there wasline to ten years was 0.0418  0.147 in IgAGN patients
a trend (P 0.079) to a worse outcome for patients withand 0.0211  0.173 (P  0.283) in the control group.
recurrence (RR 2.89, 95% CI, 0.88 to 9.44). However,
if proteinuria and plasma creatinine at six months wereIgA recurrence
also considered, IgA recurrence became not statisticallyAmong the 106 patients with IgAGN on the native
significant (P 0.214). The mean slope of the reciprocalkidneys, 57 were submitted to renal biopsy after trans-
of the plasma creatinine in the ten-year study period didplantation primarily due to an increase in plasma creati-
not differ between patients with and without recurrencenine, development of more than 0.5 g/day proteinuria or
(0.0584  0.170 vs. 0.0324  0.133).microscopic hematuria. Ten patients received a protocol
Of the four patients who lost their graft due to IgAGNbiopsy. Of the 57 biopsied patients, 37 showed a histolog-
recurrence, only one was retransplanted three years later.ical recurrence of IgAGN post-transplant. Biopsy was
Five years after retransplantation, he developed mild pro-performed at a median of 49 months (range of 4 to 213).
teinuria and microscopic hematuria, and a subsequentIn 18 cases (48.6%) the recurrence was heralded by the
graft biopsy showed a recurrence of IgAGN. At present,simultaneous appearance of microscopic hematuria and
after 92 months his plasma creatinine is 1.5 mg/dL andproteinuria, in seven cases (18.9%) by isolated micro-
scopic hematuria, in six cases (16.2%) by isolated pro- proteinuria is 2.4 g/day.
Ponticelli et al: Renal transplant in IgA nephritis 1951
Fig. 1. Ten-year patient survival probability
in renal transplant recipients with IgA glomer-
ulonephritis (solid line; IgAGN) and in trans-
plant controls () (P  NS).
Fig. 2. Ten-year graft survival probability of
renal transplant patients with IgA glomerulo-
nephritis (solid line) and controls () (P 
0.317).
Table 2. Graft survival according to the Cox model results
Variable  coefficient Standard error P RR 95% CI
Plasma creatinine at 6 months log-transformed 2.56 0.608 0.0001 12.9 3.92–42.41
Proteinuria at 6 months 	1 g/day vs. 1 g/day 1.53 0.648 0.0187 4.6 1.29–16.38
No particular therapeutic trial was attempted in pa- DISCUSSION
tients with recurrence. However, only three of 21 patients This study was based on the retrospective analysis of
treated with angiotensin-converting enzyme (ACE) in- 106 patients who underwent renal transplantation be-
hibitors lost their allograft after a mean follow-up of cause of biopsy-proven IgAGN. To the best of our knowl-
88.45 months, while 7 of 16 patients who did not receive edge, this represents the largest series reported by a
ACE inhibitors lost their graft after a mean follow-up single unit and the mean follow-up of 70 months is among
the longest reported in the literature. In this series, pa-of 92  72 months.
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Fig. 3. Time of appearance of proteinuria and/or
hematuria in patients with recurrence of IgA
glomerulonephritis. The numbers in the col-
umns refer to the number of patients with clini-
cal recurrence. One patient who received a pro-
tocol biopsy showed histological recurrence,
but was free of clinical signs of recurrence.
Table 3. Characteristics of the two IgA glomerulonephritis subgroups: Recurrence vs. non-recurrence at 10 years
Recurrence Non-recurrence P
Patients N 34 72
Age at transplantation years 33.311.4 39.911.8 0.014a
median, min–max 30, 18–56 41.5, 18–60
Sex male/female 25/9 55/17 0.898b
(73.5%/26.5%) (76.4%/23.6%)
Donor cadaveric/living 25/9 60/12 0.453b
(73.5%/26.5%) (83.3%/16.7%)
Proteinuria at 6 months g/day 0.130.5 0.110.5 0.038a
median, min–max 0, 0–1.9 0, 0–4.1
Creatinine at 6 months mg/dL 1.00.34 1.50.6 0.066a
median, min–max 1.6, 1.09–2.2 1.3, 0.8–5.3
Acute rejection N (%) 7 (20.6%) 22 (30.6%) 0.086b
Time between hemodialysis and transplantation months 28.828.3 35.835.3 0.851a
median, min–max 16, 0–134 21.5, 2–135
Follow-up months 73.538.3 59.837.6
median, min–max 80.5, 12–120 58, 12–120
a P from Cox’s univariate model
b P from the Log-rank test
Table 4. Cox model results of IgA glomerulonephritis recurrence
Variable  coefficent Standard error P RR 95% CI
Plasma creatinine at 6 months log transformed 1.29 0.645 0.0582 3.6 0.96–14.01
Proteinuria at 6 months 	1 g/day vs. 1 g/day 1.59 0.763 0.0366 4.9 1.10–22.02
Age 	30 vs. 30 years 0.96 0.352 0.0061 2.6 1.32–5.23
tients who lost their allografts in the first six months ever, others found that around five years after transplanta-
tion, recurrence of IgAGN becomes a relevant cause ofafter transplantation and those followed for less than 12
months were excluded so that the long-term outcome of graft failure [12]. In our series, the ten-year graft survival
rate was similar in patients with IgAGN and in 212 con-transplanted patients with IgAGN, which was the first
aim of the study, could be explored better. trols with various renal diseases who had been trans-
planted during the same time period and had similarThe IgAN patient outcomes after renal transplanta-
tion are controversial. Previous reports pointed out that demographic characteristics. As expected, patients with
increased plasma creatinine and proteinuria greater thanpatients with IgAGN have better kidney allograft surviv-
als than patients with other renal diseases [10, 11]. How- 1.0 g/day at six months were particularly prone to graft
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failure, the relative risk being respectively 12.9 for any likely to represent the consequence rather than the cause
of IgAGN. Of some interest, the risk of recurrence seemedlog-unit increase and 4.9. Also, the slopes of the recipro-
cal of plasma creatinine levels were not significantly dif- to be lower in patients given mycophenolate mofetil,
but the number studied was too small to permit a firmferent in the IgAGN group and in control group until
ten years. conclusion.
We found no impact of recurrent IgAGN on graft sur-Caution has been recommended in using living-related
donors in recipients with IgAGN [13, 14]. However, in vival during the ten-year follow-up period. However,
excluding death as a cause of graft failure, glomerulone-agreement with other investigators [15–17], we did not
find significant differences in long-term graft survival phritis accounted for four of the five grafts lost in those
with recurrent IgAGN and contributed to graft failurebetween living transplants in IgAGN patients and in
controls. in a fourth patient. These data show a substantial risk
of graft failure in the long-term for patients with IgAGNThe risk of recurrence of IgAGN on transplanted kid-
neys has been differently estimated, ranging between recurrence.
In conclusion, this study shows the following: (1) The13% [2, 14, 18] and more than 60% [15, 19] in different
series. These variable results were strongly influenced results of renal transplantation at ten years are similar
in patients with IgAGN and in patients with standardby the different indications to kidney allograft biopsy,
by the small number of patients investigated, and by the renal diseases. (2) Living-donor renal transplants give
similar results in IgAGN. (3) At least 35% of patientsdifferent lengths of follow-up time. The only way to know
the true rate of recurrence for certain would be to submit with IgAGN show a recurrence of the disease in the
transplanted kidney, which generally becomes clinicallypatients to serial graft biopsies every year or so, indefi-
nitely. Clearly, such an approach would meet ethical evident within six years. (4) Younger patients are at a
higher risk for recurrence of IgAGN. (5) Recurrencechallenges and has never been followed. In our experi-
ence, we tended to submit to kidney graft biopsy all does not affect graft survival or function up to ten years.
patients showing proteinuria, dysmorphic erythrocyturia
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